FDA advisory committee says risks of Novo Nordisk’s once-weekly insulin outweigh benefits in type 1 diabetes patients

An FDA ad­vi­so­ry com­mit­tee on Fri­day vot­ed not to rec­om­mend No­vo Nordisk’s once-week­ly in­sulin in­jec­tion in type 1 di­a­betes pa­tients.

No­vo has pitched its can­di­date as a more con­ve­nient al­ter­na­tive to dai­ly in­sulin dos­es, in­clud­ing its prod­uct Tre­si­ba. But com­mit­tee mem­bers in a 7-4 vote said that the ben­e­fits of the in­sulin, called isodec, did not out­weigh the risks in type 1 di­a­betes pa­tients, who pro­duce lit­tle to no in­sulin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.